Background: Overall deployed stent length has been reported as one of the common predictors for restenosis and poor clinical outcomes in bare metal stent. Recently, a few data showed the same results after drug-eluting stent (DES) implantation. The aim of this study is to evaluate the long-term outcomes after DES overlapping, and to compare the efficacy between sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES). Methods: Four hundred twenty seven patients (male 65.1%, age 63짹10) were consecutively enrolled in three interventional cardiology centers since April 2003 to July 2005. All the patients were divided into three groups: group 1 SESs overlap, group 2 PESs overlap, group 3 SES and PES overlap. 12 months clinical outcomes and angiographic follow-up results were analyzed. Results: See the following table. 12months clinical follow-up was available in 100%, angiographic follow up in 53.2%. Conclusions: SES overlapping implantation showed lower long-term adverse outcomes than PES overlapping. The incidence of adverse outcomes in overall DES overlapping (5.4%) was not different in comparing to single stent procedure. DES overlapping is relatively safe procedure in the management of long coronary lesions.